267 related articles for article (PubMed ID: 18204490)
1. Tumour endoproteases: the cutting edge of cancer drug delivery?
Atkinson JM; Siller CS; Gill JH
Br J Pharmacol; 2008 Apr; 153(7):1344-52. PubMed ID: 18204490
[TBL] [Abstract][Full Text] [Related]
2. Prodrug strategies in cancer therapy.
Denny WA
Eur J Med Chem; 2001; 36(7-8):577-95. PubMed ID: 11600229
[TBL] [Abstract][Full Text] [Related]
3. Beta-glucuronidase-mediated drug release.
de Graaf M; Boven E; Scheeren HW; Haisma HJ; Pinedo HM
Curr Pharm Des; 2002; 8(15):1391-403. PubMed ID: 12052215
[TBL] [Abstract][Full Text] [Related]
4. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies.
Tietze LF; Krewer B
Anticancer Agents Med Chem; 2009 Mar; 9(3):304-25. PubMed ID: 19275523
[TBL] [Abstract][Full Text] [Related]
5. Recent trends in targeted anticancer prodrug and conjugate design.
Singh Y; Palombo M; Sinko PJ
Curr Med Chem; 2008; 15(18):1802-26. PubMed ID: 18691040
[TBL] [Abstract][Full Text] [Related]
6. Current prodrug design for drug discovery.
Hsieh PW; Hung CF; Fang JY
Curr Pharm Des; 2009; 15(19):2236-50. PubMed ID: 19601825
[TBL] [Abstract][Full Text] [Related]
7. Prodrugs: a challenge for the drug development.
Zawilska JB; Wojcieszak J; Olejniczak AB
Pharmacol Rep; 2013; 65(1):1-14. PubMed ID: 23563019
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.
Hunter FW; Wouters BG; Wilson WR
Br J Cancer; 2016 May; 114(10):1071-7. PubMed ID: 27070712
[TBL] [Abstract][Full Text] [Related]
9. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies.
Denny WA; Wilson WR
J Pharm Pharmacol; 1998 Apr; 50(4):387-94. PubMed ID: 9625483
[TBL] [Abstract][Full Text] [Related]
10. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors.
de Groot FM; Damen EW; Scheeren HW
Curr Med Chem; 2001 Jul; 8(9):1093-122. PubMed ID: 11472243
[TBL] [Abstract][Full Text] [Related]
11. Development of prodrugs for enzyme-mediated, tumor-selective therapy.
Yoon KJ; Potter PM; Danks MK
Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):107-13. PubMed ID: 15777218
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Preclinical Evaluation of a Highly Improved Anticancer Prodrug Activated by Histone Deacetylases and Cathepsin L.
Ueki N; Wang W; Swenson C; McNaughton C; Sampson NS; Hayman MJ
Theranostics; 2016; 6(6):808-16. PubMed ID: 27162551
[TBL] [Abstract][Full Text] [Related]
13. Strategies on the development of small molecule anticancer drugs for targeted therapy.
Lu YH; Gao XQ; Wu M; Zhang-Negrerie D; Gao Q
Mini Rev Med Chem; 2011 Jun; 11(7):611-24. PubMed ID: 21699492
[TBL] [Abstract][Full Text] [Related]
14. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.
Brennen WN; Rosen DM; Wang H; Isaacs JT; Denmeade SR
J Natl Cancer Inst; 2012 Sep; 104(17):1320-34. PubMed ID: 22911669
[TBL] [Abstract][Full Text] [Related]
15. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2.
Andresen TL; Jensen SS; Kaasgaard T; Jørgensen K
Curr Drug Deliv; 2005 Oct; 2(4):353-62. PubMed ID: 16305438
[TBL] [Abstract][Full Text] [Related]
16. Prodrugs for improving tumor targetability and efficiency.
Mahato R; Tai W; Cheng K
Adv Drug Deliv Rev; 2011 Jul; 63(8):659-70. PubMed ID: 21333700
[TBL] [Abstract][Full Text] [Related]
17. Prodrug design of phenolic drugs.
Férriz JM; Vinsová J
Curr Pharm Des; 2010; 16(18):2033-52. PubMed ID: 20443775
[TBL] [Abstract][Full Text] [Related]
18. ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.
Peng X; Gandhi V
Ther Deliv; 2012 Jul; 3(7):823-33. PubMed ID: 22900465
[TBL] [Abstract][Full Text] [Related]
19. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
[TBL] [Abstract][Full Text] [Related]
20. Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria.
Lehouritis P; Stanton M; McCarthy FO; Jeavons M; Tangney M
J Control Release; 2016 Jan; 222():9-17. PubMed ID: 26655063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
